So, you, as a major shareholder, prefers the information of Cynata's website is misleading, inaccurate and dated?
You're right - it fits.
And yep, it's Mesoblast's fault. Somehow. Noted?
Glad we cleared that up.
The SP and lack of demand reflects this position.
If this is correct:
"Let's see how you go with Adults (many more other health issues).....hmmm, that's right, you went with easier to treat Children (Kurtzberg) and it's now the 10th year since you bought Osiris for 1x 54 patient P3 LOL, as you already inherited 2x failed P3s in Adults."
Then what is holding up Cynata's P2 FDA trial for GVHD?
Hoisted by your own petard whilst being a M.R.
CYP Price at posting:
30.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)